Скачать или смотреть New Staging Tool Available for Healthcare Providers Treating Patients With CTCL

Pamela Blair Allen, MD, MSc, Hematologist, discusses the new PROBE staging tool for cutaneous T-cell lymphoma (CTCL).

Cutaneous T-cell Lymphomas (CTCL) are rare, heterogeneous types of non-Hodgkin T-cell lymphoma that primarily manifest in the skin but can involve other disease compartments. CTCLs include a spectrum of variants. Mycosis Fungoides and Sézary Syndrome together are the most common CTCL subtypes.

Due to its challenging presentation, CTCL may be misdiagnosed, with some patients waiting 2 – 7 years for an accurate diagnosis. In an attempt to provide more information around the challenges of diagnosis and staging mycosis fungoides and Sezary Syndrome, the CTCL Staging Tool on PROBEinCTCL.com was developed help healthcare providers (HCPs) navigate the complicated process of accurately staging patients with Sézary syndrome and mycosis fungoides.

The tool takes physicians through a combination of up to 20 yes or no questions that are paired with real clinical case imagery. These questions bring physicians through the TNMB system, which evaluates the extent of disease across 4 compartments: skin (T), lymph nodes (N), visceral/metastasis (M), and blood (B). Upon completion, users are shown a staging which aligns most closely with the patient case provided and are directed to additional clinically relevant information for more guidance.

The tool draws from the National Comprehensive Cancer Network Guidelines and clinical trial design and staging recommendations from the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC), and the European Organisation for Research and Treatment of Cancer (EORTC).

Learn more here: http://bit.ly/45kmTVz

Supported by Kyowa Kirin, Inc.

August 2025, COR-US-ONC-0115